Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

The influence of matriptase-2 on prostate cancer in vitro: a possible role for β-catenin.

Webb SL, Sanders AJ, Mason MD, Jiang WG.

Oncol Rep. 2012 Oct;28(4):1491-7. doi: 10.3892/or.2012.1945. Epub 2012 Aug 2.

PMID:
22858929
2.

Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.

Webb SL, Sanders AJ, Mason MD, Jiang WG.

Mol Cell Biochem. 2013 Mar;375(1-2):207-17. doi: 10.1007/s11010-012-1544-z. Epub 2012 Dec 13.

PMID:
23238872
3.

Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.

Sanders AJ, Parr C, Martin TA, Lane J, Mason MD, Jiang WG.

J Cell Physiol. 2008 Sep;216(3):780-9. doi: 10.1002/jcp.21460.

PMID:
18449907
4.

Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.

Sanders AJ, Parr C, Davies G, Martin TA, Lane J, Mason MD, Jiang WG.

J Exp Ther Oncol. 2006;6(1):39-48.

PMID:
17228523
5.

Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.

Parr C, Sanders AJ, Davies G, Martin T, Lane J, Mason MD, Mansel RE, Jiang WG.

Clin Cancer Res. 2007 Jun 15;13(12):3568-76.

6.

Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis.

Cheng TS, Chen WC, Lin YY, Tsai CH, Liao CI, Shyu HY, Ko CJ, Tzeng SF, Huang CY, Yang PC, Hsiao PW, Lee MS.

Cancer Prev Res (Phila). 2013 May;6(5):495-505. doi: 10.1158/1940-6207.CAPR-12-0293-T. Epub 2013 Mar 6.

7.

In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.

Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K.

Int J Oncol. 2005 Oct;27(4):1061-70.

PMID:
16142324
8.

The type II transmembrane serine protease, matriptase-2: Possible links to cancer?

Sanders AJ, Webb SL, Parr C, Mason MD, Jiang WG.

Anticancer Agents Med Chem. 2010 Jan;10(1):64-9. Review.

PMID:
20015002
9.
10.

Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.

Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL, Ellis V.

Biochem J. 2010 Feb 9;426(2):219-28. doi: 10.1042/BJ20091448.

PMID:
20015050
11.

Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins.

Velasco G, Cal S, Quesada V, Sánchez LM, López-Otín C.

J Biol Chem. 2002 Oct 4;277(40):37637-46. Epub 2002 Jul 30.

12.

Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.

Tripathi M, Potdar AA, Yamashita H, Weidow B, Cummings PT, Kirchhofer D, Quaranta V.

Prostate. 2011 Feb 1;71(2):184-96. doi: 10.1002/pros.21233.

13.

Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.

Tsui KH, Chang PL, Feng TH, Chung LC, Sung HC, Juang HH.

Anticancer Res. 2008 Jul-Aug;28(4A):1993-9.

14.

Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.

Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB.

Gene. 2001 Nov 14;279(1):17-31.

PMID:
11722842
16.

A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.

Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27.

17.

Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface.

Stirnberg M, Maurer E, Horstmeyer A, Kolp S, Frank S, Bald T, Arenz K, Janzer A, Prager K, Wunderlich P, Walter J, Gütschow M.

Biochem J. 2010 Aug 15;430(1):87-95. doi: 10.1042/BJ20091565.

PMID:
20518742
18.

Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.

Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, Teng CH, Lin CH, Johnson MD, Lin CY, Lee MS.

Am J Pathol. 2010 Dec;177(6):3145-58. doi: 10.2353/ajpath.2010.100228. Epub 2010 Oct 22.

19.

The migration and invasion of human prostate cancer cell lines involves CD151 expression.

Ang J, Fang BL, Ashman LK, Frauman AG.

Oncol Rep. 2010 Dec;24(6):1593-7.

PMID:
21042756
20.

Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression.

Kaulfuss S, von Hardenberg S, Schweyer S, Herr AM, Laccone F, Wolf S, Burfeind P.

Oncogene. 2009 Nov 12;28(45):3971-82. doi: 10.1038/onc.2009.254. Epub 2009 Aug 24.

PMID:
19701244

Supplemental Content

Support Center